Enobosarm, MK-2866, also known as ostarine, is an investigational selective androgen receptor modulator (SARM) from GTX, Inc for treatment of conditions such as muscle wasting and osteoporosis. While GTx has not formally disclosed the structure of ostarine, the chemical composition of ostarine is revealed in patent databases such the WIPO and discussed by Zhang et al., 2009 in the primary literature.Various SARM chemotypes exist (aryl propionamides, quinolines, quinolinones, bicyclic hydantoins), though aryl propionamides such as ostarine, andarine/S-4, and S-23 represent some of the most advanced putative therapeutics under investigation. In terms of atom connectivity, enobosarm differs from andarine by cyano substitutions on the phenyl rings as it replaces both the nitro and acetamido moieties.
Androgen receptor activation
Binding and activation of the Androgen receptor alters the expression of genes and increases protein synthesis which builds muscle. In essence, SARMS like ostarine cause muscle growth in the same manner as steroids, however unlike testosterone and other anabolic steroids, SARMS do not produce the growth effect on prostate and other secondary sexual organs.
Ostarine in particular exerts its anabolic effects on muscle tissue almost exclusively. So not only does it represent a new potential treatment option for a wide spectrum of conditions from muscle wasting diseases (from age-related to AIDS or cancer-related), but is also has immense potential for muscle building for bodybuilders, fitness, athletes and an agent to minimize atrophy during recovery periods from serious surgery or similar situations.
Ostarine has a half-life of about one day.
*All prices in Canadian dollars. The information presented here is intended for educational / informational purposes only